Drug Resistance After Nevirapine in Pregnant Women
Author Information
Author(s): Rajesh Lakshmi, Ramesh K. Hanna, Luke Elizabeth Narayanan, P.R. Swaminathan, Soumya
Primary Institution: Tuberculosis Research Centre (ICMR), Chennai, India
Hypothesis
What is the pattern and prevalence of HIV drug resistance in pregnant women exposed to single dose nevirapine?
Conclusion
A high rate of NNRTI class resistance was observed among women treated with single-dose nevirapine, despite no baseline drug resistance.
Supporting Evidence
- No major mutations were observed in any drug class at baseline.
- 33% of women treated with Sd-NVP developed NNRTI resistance mutations post-delivery.
- None of the infants tested were found to be HIV-positive.
Takeaway
When pregnant women took a single dose of nevirapine to prevent passing HIV to their babies, many developed resistance to the drug afterward.
Methodology
HIV-infected, ART-naive primigravidae aged 18-25 were recruited and tested for drug resistance during pregnancy and one month after delivery.
Potential Biases
Follow-up was challenging as many women delivered in cities and returned to their native places.
Limitations
The study had a small sample size and only 20 specimens were analyzable.
Participant Demographics
HIV-infected pregnant women, ART-naive, aged 18-25, attending government antenatal clinics.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI 22-44%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website